CA2407449A1 - Nouveaux composes - Google Patents

Nouveaux composes Download PDF

Info

Publication number
CA2407449A1
CA2407449A1 CA002407449A CA2407449A CA2407449A1 CA 2407449 A1 CA2407449 A1 CA 2407449A1 CA 002407449 A CA002407449 A CA 002407449A CA 2407449 A CA2407449 A CA 2407449A CA 2407449 A1 CA2407449 A1 CA 2407449A1
Authority
CA
Canada
Prior art keywords
leu
ser
gly
ala
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002407449A
Other languages
English (en)
Inventor
Pankaj Agarwal
Paul R. Murdock
Safia K. Rizvi
Randall F. Smith
Zhaoying Xiang
Karen S. Kabnick
Ying-Ta Lai
Qing Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2407449A1 publication Critical patent/CA2407449A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes

Abstract

L'invention concerne des polypeptides et des polynucléotides des gènes décrits dans le tableau I, ainsi que des procédés de production de ces polypeptides au moyen de techniques de recombinaison. L'invention concerne également des procédés d'utilisation de polypeptides et des polynucléotides desdits gènes dans des méthodes diagnostiques.
CA002407449A 2000-04-27 2001-04-26 Nouveaux composes Abandoned CA2407449A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US19996300P 2000-04-27 2000-04-27
US60/199,963 2000-04-27
US20333600P 2000-05-11 2000-05-11
US60/203,336 2000-05-11
US20708700P 2000-05-25 2000-05-25
US60/207,087 2000-05-25
US20754600P 2000-05-26 2000-05-26
US60/207,546 2000-05-26
PCT/US2001/013360 WO2001081363A1 (fr) 2000-04-27 2001-04-26 Nouveaux composes

Publications (1)

Publication Number Publication Date
CA2407449A1 true CA2407449A1 (fr) 2001-11-01

Family

ID=27498358

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002407449A Abandoned CA2407449A1 (fr) 2000-04-27 2001-04-26 Nouveaux composes

Country Status (15)

Country Link
EP (1) EP1276755A4 (fr)
JP (1) JP2003530869A (fr)
KR (1) KR20030032940A (fr)
CN (1) CN1439017A (fr)
AU (1) AU2001257265A1 (fr)
BR (1) BR0110402A (fr)
CA (1) CA2407449A1 (fr)
CZ (1) CZ20023548A3 (fr)
HK (1) HK1053840A1 (fr)
HU (1) HUP0300595A3 (fr)
IL (1) IL152416A0 (fr)
MX (1) MXPA02010692A (fr)
NO (1) NO20025151L (fr)
PL (1) PL358580A1 (fr)
WO (1) WO2001081363A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558936B1 (en) * 1999-10-01 2003-05-06 Millennium Pharmaceuticals, Inc. Human lipase proteins, nucleic acids encoding them, and uses of both of these
US6630335B1 (en) 2000-02-11 2003-10-07 Millennium Pharmaceuticals, Inc. 14171 protein kinase, a novel human protein kinase and uses thereof
NZ523122A (en) * 2000-06-22 2004-06-25 Smithkline Beecham Corp Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases
AU2001271623A1 (en) * 2000-06-30 2002-01-14 Incyte Genomics, Inc. Human extracellular matrix (ecm)-related tumor marker
WO2002012330A2 (fr) * 2000-08-04 2002-02-14 Zymogenetics, Inc. Zzp1, proteine humaine secretee
CA2420543C (fr) * 2000-08-22 2013-04-02 Agensys, Inc. Acide nucleique et proteine correspondante nomme 158p1d7 servant dans le traitement et la detection du cancer de la vesicule et d'autres cancers
US7358353B2 (en) 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
WO2002026826A2 (fr) * 2000-09-27 2002-04-04 Curagen Corporation Nouvelles proteines et acides nucleiques codant pour celles-ci
US6875570B2 (en) 2000-09-27 2005-04-05 Curagen Corporation Proteins and nucleic acids encoding same
JP2004514448A (ja) * 2000-11-28 2004-05-20 アムジェン　インコーポレイテッド トランスフォーミング増殖因子β関連分子およびその使用
WO2002072769A2 (fr) * 2001-03-08 2002-09-19 Immunex Corporation Polypeptides du type serpine humaine
US6921807B2 (en) 2001-03-29 2005-07-26 Zymogenetics, Inc. Proteinase inhibitor ZSERP9
US20020172995A1 (en) * 2001-05-17 2002-11-21 Wei Shao Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
WO2003004527A2 (fr) * 2001-07-06 2003-01-16 Nsgene A/S Nouveaux facteurs neurotrophiques
US20030215852A1 (en) * 2002-04-01 2003-11-20 Wyeth Novel pancortin-Pablo protein interactions and methods of use thereof
WO2004072263A2 (fr) * 2003-02-10 2004-08-26 Agensys, Inc. Acide nucleique et proteine correspondante dite 158p1d7, utiles pour le traitement et la detection de cancers de la vessie et autres
WO2004069869A1 (fr) * 2003-02-10 2004-08-19 Taisho Pharmaceutical Co., Ltd. Gene provoquant l'apoptose et son utilisation
WO2005012344A1 (fr) * 2003-08-01 2005-02-10 Zymogenetics, Inc. Proteine zacrp11 liee au complement d'adipocyte
US7399469B2 (en) * 2004-03-26 2008-07-15 Pdl Biopharma, Inc. Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer
SG11201501286PA (en) 2012-08-23 2015-05-28 Agensys Inc Antibody drug conjugates (adc) that bind to 158p1d7 proteins
EP3400068A1 (fr) * 2016-01-06 2018-11-14 Yeda Research and Development Co., Ltd. Compositions et méthodes pour le traitement d'affections malignes, autoimmunes et inflammatoires
CN108178797B (zh) * 2017-12-29 2020-12-01 西南大学 一种抗家蚕BmSRC多克隆抗血清、制备方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830744A (en) * 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
AU6782894A (en) * 1994-05-05 1995-11-29 Human Genome Sciences, Inc. Human dnase
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides

Also Published As

Publication number Publication date
EP1276755A4 (fr) 2004-03-31
CZ20023548A3 (cs) 2003-05-14
MXPA02010692A (es) 2003-03-10
HK1053840A1 (zh) 2003-11-07
HUP0300595A3 (en) 2007-06-28
PL358580A1 (en) 2004-08-09
NO20025151D0 (no) 2002-10-25
WO2001081363A1 (fr) 2001-11-01
IL152416A0 (en) 2003-05-29
EP1276755A1 (fr) 2003-01-22
JP2003530869A (ja) 2003-10-21
AU2001257265A1 (en) 2001-11-07
HUP0300595A2 (hu) 2003-06-28
CN1439017A (zh) 2003-08-27
NO20025151L (no) 2002-12-13
KR20030032940A (ko) 2003-04-26
BR0110402A (pt) 2003-02-11

Similar Documents

Publication Publication Date Title
CA2407449A1 (fr) Nouveaux composes
US20050260668A1 (en) Novel compounds
US20010012628A1 (en) sbgFGF-19a
US20050255558A1 (en) Novel compounds
EP1255771A1 (fr) Nouveaux composes
NZ523122A (en) Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases
WO2001079454A1 (fr) Nouveaux composes
US20050260714A1 (en) Novel compounds
US20050214905A1 (en) Novel compounds
EP1299530A2 (fr) Nouveaux composes
US20030219862A1 (en) Novel compounds
ZA200208657B (en) Novel compounds.
US20070292921A1 (en) tRNA synthetases, metRS
US20040072999A1 (en) Novel protein inhibitor of apoptosis proteins
US20020004223A1 (en) FHAR1, a new ring finger protein
GB2365010A (en) Human TREK2 polypeptides
WO2001072963A2 (fr) Nouvelle uridine kinase humaine
WO2001096563A1 (fr) Scramblase 2
GB2373502A (en) Suppressor of cytokine signalling 4 (SOCS4)
WO2001053471A1 (fr) Polypeptide metrs appartenant aux arnt-synthetases
EP1276761A2 (fr) Nouvelle proteine a domaine bromo
WO2001070771A2 (fr) Ligand de proteine fixant le calcium a induction neuronale aigue de type 1
CA2426321A1 (fr) Mfq-114, proteine humaine du type ajuba
GB2377444A (en) Chemokine-family polypeptide
WO2001012645A1 (fr) POLYPEPTIDES sbhPARS2 ET POLYNUCLEOTIDES sbhPARS2 HUMAINS

Legal Events

Date Code Title Description
FZDE Discontinued